David Lambeth
Corporate Officer/Principal at Emory University School of Medicine
Profile
David Lambeth is the founder of Calliditas Therapeutics Suisse SA, which was founded in 2006.
He is currently a Professor at Emory University School of Medicine, where he has been working since 1980.
Dr. Lambeth received a doctorate degree from Duke University.
David Lambeth active positions
Companies | Position | Start |
---|---|---|
Emory University School of Medicine | Corporate Officer/Principal | 01/01/1980 |
Former positions of David Lambeth
Companies | Position | End |
---|---|---|
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Founder | - |
Training of David Lambeth
Duke University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Health Technology |
- Stock Market
- Insiders
- David Lambeth